Top

Published in:

01-03-2016 | Mini-review

Treatment of gastrointestinal autonomic neuropathy

Author: Hans Törnblom

Published in: Diabetologia | Issue 3/2016

Abstract

The symptoms caused by gastrointestinal autonomic neuropathy in diabetes mellitus is important to highlight since it affects a large proportion of people with diabetes, regardless of whether this is type 1 or type 2. Gastroparesis and general signs of bowel dysfunction, such as constipation, diarrhoea and abdominal pain are most often encountered and involve both pharmacological and non-pharmacological treatment options. This mini-review summarises a presentation given at the ‘Diagnosis and treatment of autonomic diabetic neuropathy in the gut’ symposium at the 2015 annual meeting of the EASD. It is accompanied by another mini-review on a topic from this symposium (by Azpiroz and Malagelada, DOI: 10.1007/s00125-015-3831-1) and a commentary by the Session Chair, Péter Kempler (DOI: 10.1007/s00125-015-3826-y).

Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10:712–721.e4CrossRefPubMed

Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161:1989–1996CrossRefPubMed

Pasricha PJ, Colvin R, Yates K et al (2011) Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 9:567–576.e1-4PubMedCentralCrossRefPubMed

Abrahamsson H (2007) Treatment options for patients with severe gastroparesis. Gut 56:877–883PubMedCentralCrossRefPubMed

Parkman HP, Yates KP, Hasler WL et al (2011) Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 141:486–498, 498.e1-7CrossRefPubMed

Olausson EA, Storsrud S, Grundin H, Isaksson M, Attvall S, Simren M (2014) A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol 109:375–385CrossRefPubMed

Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association (2004) American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 127:1592–1622CrossRefPubMed

Janssen P, Harris MS, Jones M et al (2013) The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 108:1382–1391CrossRefPubMed

Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A (1982) Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 96:444–446CrossRefPubMed

10.

McCallum RW, Ricci DA, Rakatansky H et al (1983) A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 6:463–467CrossRefPubMed

11.

Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW (1985) Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 7:25–32CrossRefPubMed

12.

Perkel MS, Moore C, Hersh T, Davidson ED (1979) Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci 24:662–666CrossRefPubMed

13.

Patterson D, Abell T, Rothstein R, Koch K, Barnett J (1999) A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 94:1230–1234PubMed

14.

Janssens J, Peeters TL, Vantrappen G et al (1990) Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 322:1028–1031CrossRefPubMed

15.

Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S (1993) Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 16:1511–1514CrossRefPubMed

16.

Tack J, Vanormelingen C (2014) Management of gastroparesis: beyond basics. Curr Treat Options Gastroenterol 12:468–477CrossRefPubMed

17.

Abell T, McCallum R, Hocking M et al (2003) Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 125:421–428CrossRefPubMed

18.

Abell TL, Van Cutsem E, Abrahamsson H et al (2002) Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 66:204–212CrossRefPubMed

19.

McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T (2010) Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 8:947–954CrossRefPubMed

20.

McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I (2011) Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 9:314–319.e1CrossRefPubMed

21.

Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60:209–218CrossRefPubMed

22.

Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58:357–365CrossRefPubMed

23.

Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344–2354CrossRefPubMed

24.

Quigley EM, Vandeplassche L, Kerstens R, Ausma J (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29:315–328CrossRefPubMed

25.

Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R (2014) Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 26:21–27CrossRefPubMed

26.

Yiannakou Y, Piessevaux H, Bouchoucha M et al (2015) A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol 110:741–748PubMedCentralCrossRefPubMed

27.

Lembo AJ, Kurtz CB, Macdougall JE et al (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138:886–895.e1CrossRefPubMed

28.

Chey WD, Lembo AJ, Lavins BJ et al (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702–1712CrossRefPubMed

29.

Lacy BE, Schey R, Shiff SJ et al (2015) Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial. PLoS One 10:e0134349PubMedCentralCrossRefPubMed

30.

Bharucha AE, Low P, Camilleri M et al (2013) A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 62:708–715PubMedCentralCrossRefPubMed

31.

Lavo B, Stenstam M, Nielsen AL (1987) Loperamide in treatment of irritable bowel syndrome—a double-blind placebo controlled study. Scand J Gastroenterol Suppl 130:77–80CrossRefPubMed

32.

Tornblom H, Drossman DA (2015) Centrally targeted pharmacotherapy for chronic abdominal pain. Neurogastroenterol Motil 27:455–467CrossRefPubMed

33.

Kurlander JE, Drossman DA (2014) Diagnosis and treatment of narcotic bowel syndrome. Nat Rev Gastroenterol Hepatol 11:410–418CrossRefPubMed

34.

Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169–1180CrossRefPubMed

35.

Han X, Tong J, Zhang J et al (2011) Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice. J Neurotrauma 28:995–1007PubMedCentralCrossRefPubMed

36.

Drossman DA (2009) Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 104:2897–2902CrossRefPubMed

37.

Lunn MP, Hughes RA, Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev, Issue 1, Art. No.: CD003287. doi:10.1002/14651858.CD003287.pub4

Title: Treatment of gastrointestinal autonomic neuropathy
Author: Hans Törnblom
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 3/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-015-3828-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Adipose-derived lipocalin 14 alleviates hyperglycaemia by suppressing both adipocyte glycerol efflux and hepatic gluconeogenesis in mice

Up front March 2016

Muscle-specific inflammation induced by MCP-1 overexpression does not affect whole-body insulin sensitivity in mice

Insulitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes

Diabetic neuropathy in the gut: pathogenesis and diagnosis

Ageing is associated with molecular signatures of inflammation and type 2 diabetes in rat pancreatic islets

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials